For low and intermediate risk neuroblastoma, treatment strategies aim at delivering the minimum of therapy necessary in order to maintain an excellent survival, while diminishing treatment toxicity. For these patients, which comprise approximately one half of all newly diagnosed neuroblastoma, treatment intensity and length is adapted according to the clinical parameters stage, age, clinical symptoms, as well as tumor genetic features, with treatment ranging from observation only to more intensive treatment regimens with several courses of chemotherapy, surgical resection, radiotherapy and maintenance therapy. Fine-tuning of these treatment approaches will be based on further integration of genomic data, such as genomic copy number profiles or expression signatures. However with the discovery of more and more prognostic biomarkers, only large-scale integrative efforts will enable to combine this information to develop the clinically most meaningful and practicable approaches. It is likely that combining genomic prognostic and predictive biomarkers will lead to more precise treatment strategies.